http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108685911-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate | 2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108685911-B |
| titleOfInvention | Application of 2-[(4-tert-butylthiazol-2-yl)imino]thiazolin-4-one in pharmacy |
| abstract | The invention discloses that 2-[(4-tert-butylthiazol-2-yl)imino]thiazoline-4-one is used in the preparation of medicines for inhibiting and killing Streptococcus mutans type strains or in the preparation of biofilms for inhibiting Streptococcus mutans type strains. of the formation of pharmaceutical applications. Experiments have confirmed that the compounds of the present invention have good bacteriostatic activity and bactericidal activity against Streptococcus mutans type strains in planktonic state, and when the final concentration of the compounds in the medium reaches 4 mg/L, the inhibition rate of Streptococcus mutans biofilm reaches More than 99%. The compounds of the present invention can be used as novel leading compounds for preventing dental caries, and have broad application prospects in the preparation of oral Streptococcus mutans biofilm inhibitors. |
| priorityDate | 2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.